Patient Reported Satisfaction With Contoura LASIK Utilizing the Phorcides Analytic Software

Mann Eye Institute

Status

Completed

Conditions

Myopia

Treatments

Device: Contoura LASIK

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT05848817

PB-23-01

Details and patient eligibility

About

The objective is to determine the percentage of subjects satisfied (Completely Satisfied or Very Satisfied) with vision after Phorcides Planned Contoura LASIK.

Full description

This study is a single site, single-arm, prospective, observational study of subject satisfaction, after successful bilateral LASIK surgery. Subjects will be assessed pre-operatively, operatively and at 1 week, 1 month, and 3 months post-operatively. Clinical evaluations will include measurement of visual acuity, manifest refraction, and topography, aberrometry, and administration of the OSDI and PROWL questionnaires.

Enrollment

5 patients

Sex

All

Ages

21 to 39 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Subjects are eligible for the study if they meet the following criteria:

Note: Ocular criteria must be met in both eyes.

Appropriate candidate for uncomplicated bilateral LASIK surgery
Gender: Males and Females.
Age: 21 to 39 years of age.
Refractive error range - SE refractive errors up to 0.00 to -9.00 D with maximum cylinder up to 3.00 D and sphere ≤ -8.00 D.
If currently wearing contact lenses:
- Soft CTL wearers discontinue for minimum 3 days
- RGP CTL wearers discontinue for 1 month per decade of wear
- Stable refraction (2 consecutive manifest refractions within 0.25 SE)
- Stable K readings (2 consecutive K readings in 2 consecutive visits)
Residual bed thickness 250um or greater
Willing and able to comply with scheduled visits and other study procedures.
Pre-surgery BCDVA of 20/20 (0.00 logMAR) or better in each eye.

If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

Subjects with history of previous ocular surgery.
Subjects with topographic evidence of keratoconus, or ectasia.
Subjects with autoimmune diseases.
Subjects who are pregnant or nursing.
Systemic disease likely to affect wound healing, such as diabetes and severe atopy.
Any ocular disease (including un-controlled dry eye) which in the investigator's opinion would affect the outcome of refractive surgery.

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.